Share on StockTwits
 

Shares of Zogenix (NASDAQ:ZGNX) hit a new 52-week high during mid-day trading on Thursday, American Banking News reports. The stock traded as high as $4.17 and last traded at $4.08, with a volume of 5,232,604 shares trading hands. The stock had previously closed at $3.88.

A number of analysts have recently weighed in on ZGNX shares. Analysts at Oppenheimer upgraded shares of Zogenix from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday, November 14th. They now have a $5.00 price target on the stock. Separately, analysts at Stifel Nicolaus upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a research note to investors on Tuesday, October 29th. They now have a $5.00 price target on the stock. Finally, analysts at William Blair raised their price target on shares of Zogenix from $3.00 to $6.00 in a research note to investors on Monday, October 28th. They now have an “outperform” rating on the stock. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $5.25.

Zogenix has a 52-week low of $1.16 and a 52-week high of $3.90. The stock’s 50-day moving average is $3.18 and its 200-day moving average is $2.2. The company’s market cap is $433.3 million.

Zogenix (NASDAQ:ZGNX) last released its earnings data on Monday, November 4th. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.09) by $0.03. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $9.33 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was down 15.3% on a year-over-year basis. On average, analysts predict that Zogenix will post $-0.51 earnings per share for the current fiscal year.

Zogenix, Inc (NASDAQ:ZGNX) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.